Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
Idenix Pharmaceuticals |
---|---|
Information provided by: | Idenix Pharmaceuticals |
ClinicalTrials.gov Identifier: | NCT00118768 |
This Phase II study is being conducted in treatment-naive patients (no previous antiviral therapy for Hepatitis C infection) with genotype-1 chronic hepatitis C to evaluate the safety and effectiveness of valopicitabine alone and together with Pegylated Interferon (a drug approved by the Food and Drug Administration for the treatment of Hepatitis C infection).
Condition | Intervention | Phase |
---|---|---|
Chronic Hepatitis C |
Drug: valopicitabine Drug: Pegylated Interferon Alfa |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Open Label, Dose Comparison, Parallel Assignment, Safety/Efficacy Study |
Official Title: | A Randomized, Phase IIb Clinical Trial to Evaluate the Safety and Antiviral Activity of the Combination of Pegylated Interferon Alfa Plus NM283 (Valopicitabine) in Treatment-Naive Patients With Chronic Hepatitis C |
Ages Eligible for Study: | 18 Years to 65 Years |
Genders Eligible for Study: | Both |
Inclusion Criteria:
Exclusion Criteria:
Study ID Numbers: | NV-08A-006 |
Study First Received: | June 30, 2005 |
Last Updated: | February 27, 2009 |
ClinicalTrials.gov Identifier: | NCT00118768 History of Changes |
Health Authority: | United States: Food and Drug Administration |
Genotype-1, Chronic Hepatitis C |
Interferon-alpha Liver Diseases Interferon Type I, Recombinant Immunologic Factors Hepatitis, Chronic Interferons Hepatitis, Viral, Human Angiogenesis Inhibitors |
Antiviral Agents Hepatitis Virus Diseases Digestive System Diseases Hepatitis C Interferon Alfa-2a Hepatitis C, Chronic |
Anti-Infective Agents Interferon Type I, Recombinant Liver Diseases Flaviviridae Infections Hepatitis, Chronic Immunologic Factors Antineoplastic Agents Physiological Effects of Drugs Hepatitis, Viral, Human Therapeutic Uses Hepatitis C Angiogenesis Modulating Agents Growth Inhibitors |
Interferon-alpha RNA Virus Infections Growth Substances Interferons Antiviral Agents Angiogenesis Inhibitors Pharmacologic Actions Virus Diseases Hepatitis Digestive System Diseases Interferon Alfa-2a Hepatitis C, Chronic |